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Introduction {#sec001}
============

Bacteria in the genus *Rickettsia* are obligate intracellular alphaproteobacteria that are divided into four groups---the spotted fever group (SFG), typhus group (TG), ancestral group (AG), and transitional group (TRG) \[[@pone.0197012.ref001]\]. They inhabit arthropods (ticks, fleas, and mites), and many can be transmitted to humans and other mammals. Pathogenic species primarily target endothelial cells in the vasculature, causing a variety of vascular diseases such as typhus and Rocky Mountain spotted fever \[[@pone.0197012.ref002]\]. Despite the prevalence of rickettsial diseases throughout the world, we know little about the bacterial factors required for infection and pathogenesis.

The SFG species *Rickettsia parkeri*, a tick-borne pathogen that causes a mild form of spotted fever in humans \[[@pone.0197012.ref003],[@pone.0197012.ref004]\], is emerging as a model organism to study SFG rickettsial pathogenesis. *R*. *parkeri* can be studied under BL2 conditions and has animal models of pathogenesis that mimic aspects of human infection \[[@pone.0197012.ref005],[@pone.0197012.ref006]\]. Furthermore, the *R*. *parkeri* life cycle closely matches that of the more virulent SFG species *Rickettsia rickettsii* \[[@pone.0197012.ref007],[@pone.0197012.ref008]\], the causative agent of Rocky Mountain spotted fever. Like its more virulent relative, *R*. *parkeri* invades non-phagocytic cells and is taken into a primary phagocytic vacuole \[[@pone.0197012.ref009]\]. They then break out of this vacuole and enter the cytosol to replicate and grow \[[@pone.0197012.ref010]\]. *R*. *parkeri* and many other *Rickettsia* species also hijack the host cell actin cytoskeleton to polymerize actin tails and undergo actin-based motility \[[@pone.0197012.ref011]--[@pone.0197012.ref013]\]. During spread, motile *R*. *parkeri* move to a host cell-cell junction but then lose their actin tails before entering into a short (\~1 μm) plasma membrane protrusion that is subsequently engulfed into the neighboring cell. The bacterium then lyses the double-membrane secondary vacuole to enter the neighboring cell cytosol to begin the process of spread again \[[@pone.0197012.ref014]\]. Because of its experimental tractability and the fact that its lifecycle is indistinguishable from more virulent species, *R*. *parkeri* provides an attractive system for investigating rickettsial host-pathogen interactions.

As an obligate intracellular pathogen, *R*. *parkeri* must produce virulence factors that usurp or disrupt various host cell pathways. However, due to their obligate growth requirement, it has been challenging to genetically manipulate rickettsiae to identify the key bacterial factors that contribute to infection \[[@pone.0197012.ref015]\]. Fortunately, recent advances have expanded the genetic toolkit that can be used in the rickettsiae, allowing us to peer more directly into the molecular mechanisms that drive rickettsial biology. Chief among these advances was the development of a *Himar1 mariner*-based transposon system for random mutagenesis of rickettsial genomes \[[@pone.0197012.ref016]\]. To date, smaller-scale mutagenesis studies have been completed in the TG species *R*. *prowazekii* \[[@pone.0197012.ref016]--[@pone.0197012.ref018]\] and the SFG species *R*. *rickettsii* \[[@pone.0197012.ref018],[@pone.0197012.ref019]\].

Despite these advances, we still do not know all of the critical bacterial factors that mediate interactions with the host. Moreover, many of the genes in *R*. *parkeri* are annotated to encode hypothetical proteins, which limits our ability to rationally explore their functions. Therefore, we set out to expand the repertoire of available *R*. *parkeri* mutants using a forward genetic screen. We used the *mariner*-based transposon system \[[@pone.0197012.ref016]\] and developed a more streamlined protocol to rapidly isolate *R*. *parkeri* mutants that alter plaque size \[[@pone.0197012.ref014]\]. To date, we have isolated over 100 mutants that disrupt genes predicted to function in a variety of pathways. We have previously published our detailed analysis of three mutants--in *sca2*, *rickA*, and *sca4* \[[@pone.0197012.ref014],[@pone.0197012.ref020]\]. Here, we present the full panel of mutants to demonstrate the potential and ease of developing rickettsial transposon libraries.

Materials and methods {#sec002}
=====================

Cell lines {#sec003}
----------

Vero cells (monkey, kidney epithelial) were obtained from the University of California, Berkeley tissue culture facility and grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) containing 5% fetal bovine serum (FBS) at 37°C in 5% CO~2~.

Transposon mutagenesis in *R*. *parkeri* {#sec004}
----------------------------------------

*R*. *parkeri* Portsmouth strain was a gift from Dr. Chris Paddock (Centers for Disease Control and Prevention). Wild-type *R*. *parkeri* were expanded and purified by centrifugation through a 30% MD-76R solution, as previously described \[[@pone.0197012.ref014]\]. The pMW1650 plasmid carrying the *Himar1 mariner*-based transposon \[[@pone.0197012.ref016]\] (a gift from Dr. David Wood, University of South Alabama) was used to generate *R*. *parkeri* strains carrying transposon insertions, as previously described \[[@pone.0197012.ref014]\] and reintroduced here. To isolate small plaque mutants, we implemented a small-scale electroporation protocol. A T75 cm^2^ flask of confluent Vero cells was infected with approximately 10^7^ WT *R*. *parkeri*. When Vero cells were at least 90% rounded at 3 d post infection, they were scraped from the flask. Infected cells were spun down for 5 min at 1800 x g at 4°C and resuspended in 3--6 ml of K-36 buffer. To release bacteria, infected cells were mechanically disrupted either by passing them through a 27.5 gauge syringe needle 10 times, or by vortexing at \~2900 rpm using a Vortex Genie 2 (Scientific Industries Inc.) in a 15 ml conical tube containing 2 g of 1 mm glass beads, with two 30 s pulses and 30 s incubations in ice after each pulse. This bead disruption procedure was adopted for a majority of the screen, because it was faster and reduced the possibility of a needle stick. Host cell debris was pelleted by centrifugation for 5 min at 200 x g at 4°C. The supernatant containing *R*. *parkeri* was transferred to 1.5 ml microcentrifuge tubes and spun for 2 min at 9000 x g at 4°C. Bacterial pellets were then washed three times in cold 250 mM sucrose, resuspended in 50 μl cold 250 mM sucrose, mixed with 1 μg of pMW1650 plasmid, placed in a 0.1 cm cuvette, and electroporated at 1.8 kV, 200 ohms, 25 μF, 5 ms using a Gene Pulser Xcell (Bio-Rad). Bacteria were immediately recovered in 1.2 ml brain heart infusion (BHI) medium. For infections of confluent Vero cells in 6-well plates, medium was removed from each well, and cells were washed with phosphate-buffered saline (PBS). Electroporated bacteria (100 μl) was added to each well, and plates were placed in a humidified chamber and rocked for 30 min at 37°C. An overlay of DMEM with 5% FBS and 0.5% agarose was then added to each well. Infected cells were incubated at 33°C, 5% CO~2~ for 24 h, and then to select for transformants, a second overlay was added containing rifampicin (Sigma) to a final concentration 200 ng/ml to select for transformants. Stock solutions of rifampicin were prepared in DMSO at 25 mg/ml and stored at -20°C. After at least 3 or 4 d, plaques were visible by eye in the cell monolayer, and plaques smaller or bigger relative to neighboring plaques were harvested and re-plated for further analysis, as described below.

To isolate and expand mutant strains before mapping the sites of transposon insertion, plaques were picked and resuspended in 200 μl of BHI. Medium was aspirated from confluent Vero cells in 6-well plates, and the isolated plaque resuspension was used to infect the cells at 37°C for 30 min with rocking. Then 3 ml DMEM with 2% FBS and 200 ng/ml rifampicin was added to each well, and infections were allowed to progress until monolayers were fully infected. Infected cells were isolated using mechanical disruption as described above, except that bacteria were immediately resuspended in BHI without a sucrose wash and stored at -80°C. These plaque-purified strains were then used as described below to map the transposon insertion sites.

Semi-random nested PCR {#sec005}
----------------------

To map the transposon insertion sites, plaque-purified *R*. *parkeri* strains were boiled for 10 min and used as templates for PCR reactions. Genomic DNA at insertion sites was amplified for sequencing using semi-random nested PCR. The first "external" PCR reaction used transposon-specific primers (ExTn1 `5’-CACCAATTGCTAAATTAGCTTTAGTTCC-3`'; or ExTn2 `5’-GTGAGCTATGAGAAAGCGCCACGC-3’`) and a universal primer (Univ1 `5’-GCTAGCGGCCGCACTAGTCGANNNNNNNNNNCTTCT-3’`). Univ1 has a specific sequence at the 5' end and a random sequence near the 3' end to allow for random annealing throughout the chromosome. The first PCR reaction yielded the "external" product that served as a template in the subsequent "internal" PCR reaction using transposon-specific primers (InTn1 `5’-GCTAGCGGCCGCGGTCCTTGTACTTGTTTATAATTATCATGAG-3’`; or InTn2 `5’-GCTAGCGGCCGCCCTGGTATCTTTATAGTCCTGTCGG-3’`) and a different universal primer (Univ2 `5’-GCTAGCGGCCGCACTAGTCGA-3’`). Univ2 contains the same specific sequence as Univ1, allowing for specific amplification of the external PCR product. PCR products were cleaned using ExoSAP-IT PCR Product Cleanup Reagent (Affymetrix) and sequenced using transposon-specific primers SR095 `5’-CGCCACCTCTGACTTGAGCGTCG-3`' and SR096 `5’-CCATATGAAAACACTCCAAAAAAC-3’.` Genomic locations were determined using BLAST against the *R*. *parkeri* strain Portsmouth genome (GenBank/NCBI accession NC_017044.1).

Results {#sec006}
=======

Design of an improved transposon mutagenesis scheme {#sec007}
---------------------------------------------------

We used the pMW1650 plasmid, which carries a *Himar1 mariner*-based transposon \[[@pone.0197012.ref016]\], to randomly mutate the *R*. *parkeri* genome. pMW1650 encodes the *Himar1* transposase, a transposon cassette that contains the *R*. *prowazekii arr-2* rifampin resistance gene, and a variant of green fluorescent protein (GFPuv) \[[@pone.0197012.ref016]\] ([Fig 1A](#pone.0197012.g001){ref-type="fig"}). The first reported application of this system in *R*. *prowazekii* \[[@pone.0197012.ref016]\] and *R*. *rickettsii* \[[@pone.0197012.ref018]\] yielded some transposon mutants, but we sought to improve the mutagenesis scheme to increase the chances of identifying genes important for infection. Therefore, we developed a simple and rapid procedure to extract bacteria from infected host cells \[[@pone.0197012.ref014]\]. In the past, we had purified *R*. *parkeri* from infected host cells using an hours-long process involving mechanical disruption and density gradient centrifugation prior to electroporation \[[@pone.0197012.ref021]\]. In recent work, we optimized this procedure to more quickly isolate and electroporate bacteria and re-infect host cells in under an hour \[[@pone.0197012.ref014]\]. To mechanically disrupt infected cells, we either passed infected cells through a syringe needle or vortexed cells in the presence of 1 mm glass beads. Samples were then spun at low speed for 5 min to pellet host cell debris, followed by a 2 min high-speed spin to pellet bacteria. Bacteria were then quickly washed 2--3 times in cold sucrose prior to electroporation.

![Transposon mutagenesis of *R*. *parkeri*.\
(A) Map of the pMW1650 plasmid used in this study for transposon mutagenesis (IR, inverted repeats). (B) Experimental scheme for transposon mutagenesis and isolation of individual mutants.](pone.0197012.g001){#pone.0197012.g001}

To identify genes involved in infection, we screened for transformants that showed altered plaque size and/or morphology ([Fig 1B](#pone.0197012.g001){ref-type="fig"}). We predicted that plaque size changes would result from defects at different stages of the rickettsial life cycle, including in intracellular growth, replication, motility, and/or spread. To screen for such mutants, pMW1650-electroporated bacteria were immediately used to setup plaque assays in the presence of rifampicin to select for transformants. Plaque size was monitored visually over the course of 3--9 days, and those displaying a small plaque (Sp) or big plaque (Bp) phenotype relative to their neighbors were selected for expansion. After independently repeating this process 7 times, 120 Sp mutant and 2 Bp mutants were selected for further analysis, as detailed below.

Expansion and mapping of the transposon mutants {#sec008}
-----------------------------------------------

To expand the isolated transformants, plaques were picked and transferred to uninfected host cells to propagate each bacterial strain. Once the host cells were \>75% infected, bacteria were purified using the rapid isolation procedure outlined above. Nine isolates did not grow in this expansion procedure, possibly due to a lack of live bacteria in the original plaque or poor isolation of the infected cells. The remaining transformants could be expanded, and for these the transposon insertion site was mapped using a semi-random nested PCR protocol. In short, the junctions between the transposon and the flanking genomic regions were amplified via two nested PCR reactions, using transposon-specific and universal primers ([Fig 2A](#pone.0197012.g002){ref-type="fig"}). PCR products were sent directly for sequencing. Mapping of the transposon insertion sites to the *R*. *parkeri* chromosome (accession number CP003341) revealed no preference for specific regions ([Fig 2B](#pone.0197012.g002){ref-type="fig"}), similar to what was observed in *R*. *rickettsii* \[[@pone.0197012.ref018],[@pone.0197012.ref019]\] and *R*. *prowazekii* \[[@pone.0197012.ref016],[@pone.0197012.ref018]\]. Using this procedure, we identified the transposon insertion sites for 106 mutants. For 6 isolates the transposon insertion site could not be mapped, and the strains did not express GFP~uv~ (data not shown), suggesting these were spontaneous rifampicin-resistant strains. Of the 106 transposon mutations mapped, 81 were within the coding regions of 75 distinct genes and 25 were in intergenic regions ([Table 1](#pone.0197012.t001){ref-type="table"}). These results lay the groundwork for critical follow-up studies (e.g. purification of clonal populations, complementation, phenotypic analyses, etc.) required for revealing gene function. They also highlight that transposon mutagenesis can be readily adapted for large-scale forward genetic screening in *R*. *parkeri*.

![Mapping the transposon insertion sites.\
(A) Diagram showing the insertion of the transposon cassette into a chromosomal region (in grey). Primers specific to the transposon ends were paired with universal primers to amplify the chromosome- transposon junctions (red triangles), using semi-random nested PCR. Two nested PCR reactions were done to improve amplification of the chromosome-transposon junction directly from boiled bacteria. (B) *R*. *parkeri* chromosomal map showing all transposon insertion sites (see red lines) identified in this screen.](pone.0197012.g002){#pone.0197012.g002}
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###### Transposon insertion sites in *R*. *parkeri*.

![](pone.0197012.t001){#pone.0197012.t001g}

  Name    Genome position    Gene symbol                                         Gene product description
  ------- ------------------ --------------------------------------------------- --------------------------------------------------------------
  Sp1     101427             MC1_00610                                           Putative cytoplasmic protein
  Sp2     112315             MC1_00650 [\*\*](#t001fn002){ref-type="table-fn"}   Surface cell antigen 2 (Sca2)
  Sp3     681322--681323     MC1_03895                                           Single-stranded-DNA-specific exonuclease RecJ
  Sp6     365840             MC1_02010                                           Cytochrome c1, heme protein
  Sp7     670632             MC1_03810                                           Folylpolyglutamate synthase
  Sp8     1047805--1047806   Intergenic                                          n/a
  Sp9     151196--151197     MC1_00820                                           VirB6 Type IV secretory pathway (rvhB6e)
  Sp10    491813             Intergenic                                          n/a
  Sp11    1136147            MC1_06660                                           DNA polymerase I
  Sp13    563189--563190     MC1_03195                                           RND efflux transporter
  Sp14    518698--518699     MC1_02960                                           CTP synthetase
  Sp15    520939             MC1_02980                                           Hypothetical protein
  Sp17    1248850--1248851   MC1_07220                                           Transcriptional regulator
  Sp18    70364              MC1_00450                                           Hypothetical protein
  Sp19    654506--654507     MC1_03740                                           Antigenic heat-stable 120 kDa protein (Sca4)
  Sp20    531536             MC1_03025 [\*\*](#t001fn002){ref-type="table-fn"}   ampG protein
  Sp21    20179              Intergenic                                          n/a
  Sp22    29609              MC1_00175                                           F0F1 ATP synthase subunit B
  Sp23    474265             MC1_02665                                           Outer membrane assembly protein
  Sp24    753916             Intergenic                                          n/a
  Sp25    728290             MC1_04100                                           Isopentenyl pyrophosphate isomerase
  Sp26    33338              MC1_00210                                           Transcriptional regulator
  Sp27    30722              Intergenic                                          n/a
  Sp28    301811             MC1_01650                                           Protease
  Sp29    225255             MC1_01180                                           Acriflavin resistance protein D
  Sp30    886852             Intergenic                                          n/a
  Sp31    262955--262956     MC1_01410                                           Hypothetical protein
  Sp33    299510             MC1_01640                                           Putative toxin of toxin-antitoxin (TA) system
  Sp34    888003             MC1_05085 [\*\*](#t001fn002){ref-type="table-fn"}   Actin polymerization protein RickA
  Sp35    589425             MC1_03370                                           Thiol:disulfide interchange protein dsbA
  Sp36    230327             MC1_01215                                           Prolyl endopeptidase
  Sp37    637085             MC1_03670                                           Hypothetical protein
  Sp38    292360--292361     MC1_01595                                           S-adenosylmethionine:tRNA ribosyltransferase-isomerase
  Sp39    912985             MC1_05235                                           Hypothetical protein (RARP-2)
  Sp40    1279632            Intergenic                                          n/a
  Sp41    995818             Intergenic                                          n/a
  Sp42    372020             MC1_02055 [\*\*](#t001fn002){ref-type="table-fn"}   GTP-binding protein LepA
  Sp43    651603--651604     MC1_03735                                           ADP, ATP carrier protein
  Sp44    868641             MC1_04970                                           HAD-superfamily hydrolase
  Sp45    761156             MC1_04295                                           Microcin C7 resistance protein
  Sp46    852817             MC1_04870                                           Methylated-DNA-protein-cysteine methyltransferase
  Sp47    856486             MC1_04920                                           Hypothetical protein
  Sp48    243782--243780     MC1_01300                                           DNA repair protein RecN
  Sp49    687339             MC1_03930                                           Hypothetical protein
  Sp50    1158028            MC1_06730                                           Hypothetical protein
  Sp51    888088             MC1_05085 [\*\*](#t001fn002){ref-type="table-fn"}   Actin polymerization protein RickA
  Sp52    346470             Intergenic                                          n/a
  Sp53    793762             MC1_04525                                           Hypothetical protein
  Sp54    1258878            MC1_07285                                           Hypothetical protein
  Sp55    1245896            MC1_07200                                           tig Trigger factor
  Sp56    1243741--1243742   Intergenic                                          n/a
  Sp57    1004249--1004250   Intergenic                                          n/a
  Sp58    1273429            MC1_07360                                           NAD(P) transhydrogenase subunit alpha
  Sp59    1181227            Intergenic                                          n/a
  Sp60    1158028            MC1_01115                                           Hypothetical protein
  Sp62    350030--350031     MC1_01915                                           Cytochrome c oxidase assembly protein
  Sp63    109070             MC1_00650 [\*\*](#t001fn002){ref-type="table-fn"}   Surface cell antigen (Sca2)
  Sp64    314932             MC1_01745 [\*\*](#t001fn002){ref-type="table-fn"}   Ankyrin repeat-containing protein (RARP-1)
  Sp65    726967             Intergenic                                          n/a
  Sp66    615509--615510     MC1_03545                                           Hypothetical protein
  Sp71    371351             MC1_02055 [\*\*](#t001fn002){ref-type="table-fn"}   GTP-binding protein LepA
  Sp72    83786              MC1_00525                                           Stage 0 sporulation protein J
  Sp73    655844             MC1_03745                                           Putative transcriptional regulator
  Sp74    991759--991760     MC1_05745                                           Hypothetical protein
  Sp75    251100             MC1_01335                                           Ankyrin repeat-containing protein
  Sp76    9674               Intergenic                                          n/a
  Sp78    672659             Intergenic                                          n/a
  Sp79    65481              Intergenic                                          n/a
  Sp80    1210788--1210789   MC1_07040                                           Outer membrane protein OmpA
  Sp81    365135             MC1_02000                                           Cytochrome b
  Sp82    549578--549579     MC1_03115                                           Cytochrome c oxidase polypeptide
  Sp83    480829             MC1_02715                                           Hypothetical protein
  Sp84    689140             Intergenic                                          n/a
  Sp85    514488             Intergenic                                          n/a
  Sp88    241435             MC1_01295                                           Thermostable carboxypeptidase
  Sp90    1127301            MC1_06610                                           Hypothetical protein
  Sp91    82796              MC1_00515                                           16S rRNA methyltransferase GidB
  Sp92    1229489--1229490   MC1_07110                                           17 kDa surface antigen
  Sp93    1223170            MC1_07070                                           Undecaprenyl-phosphate alpha-N-acetylglucosaminyltransferase
  Sp94    774831             Intergenic                                          n/a
  Sp95    902617             MC1_05150                                           Patatin b1
  Sp96    561640--561641     MC1_03180                                           Hypothetical protein
  Sp97    641129--641130     MC1_03685                                           miaA tRNA delta(2)-isopentenylpyrophosphate transferase 
  Sp98    34100--34101       MC1_00220                                           Putative methyltransferase
  Sp99    1104365            Intergenic                                          n/a
  Sp100   375061             Intergenic                                          n/a
  Sp101   152889--152890     Intergenic                                          n/a
  Sp102   406474--406475     MC1_02260                                           DNA mismatch repair protein MutS
  Sp103   662735             MC1_03780                                           Hypothetical protein
  Sp104   1161553            MC1_06745                                           Hypothetical protein
  Sp105   593543--593544     MC1_03405                                           Acylamino acid-releasing protein
  Sp106   1045462--1045463   MC1_06065                                           Outer membrane protein OmpB
  Sp107   531709             MC1_03025 [\*\*](#t001fn002){ref-type="table-fn"}   ampG protein
  Sp108   1177263            MC1_06810                                           F0F1 ATP synthase subunit beta
  Sp109   54288--54289       MC1_00370 [\*\*](#t001fn002){ref-type="table-fn"}   Chaperone ClpB
  Sp111   854916             Intergenic                                          n/a
  Sp112   55657              MC1_00370 [\*\*](#t001fn002){ref-type="table-fn"}   Chaperone ClpB
  Sp113   319455             MC1_01760                                           Histidine kinase sensor protein
  Sp114   765596             MC1_04335                                           Ribonuclease D
  Sp115   229548             Intergenic                                          n/a
  Sp116   314408             MC1_01745 [\*\*](#t001fn002){ref-type="table-fn"}   Ankyrin repeat-containing protein (RARP-1)
  Sp117   733347             MC1_04135                                           Hypothetical protein
  Sp118   695571             Intergenic                                          n/a
  Sp119   231259             MC1_01235                                           Prolyl endopeptidase
  Sp120   27839              MC1_00155                                           Hypothetical protein
  Bp2     756531             MC1_04275                                           Hypothetical protein

Spontaneous rifampicin resistant mutants: Sp4-5, 69--70, 86, Bp1. Clones that did not expand: Sp16, 32, 61, 67--68, 77, 87, 89, 110. Mapping for Sp12 revealed two different insertion sites and was not included in the list above.

\*\* Indicates more than one isolated transposon mutant/gene. n/a, not applicable.

Discussion {#sec009}
==========

A critical barrier to identifying and characterizing virulence factors in obligate intracellular bacterial pathogens has been the inability to easily manipulate their genomes. In this study, we sought to overcome this barrier and harness recent advances in rickettsial genetics to build a library of transposon mutants of the SFG *Rickettsia* species, *R*. *parkeri*. We streamlined previous protocols to introduce a *mariner*-based transposon into the *R*. *parkeri* genome and isolated 106 transposon insertion mutations. Our study represents the first such transposon mutant library in this species, and the most extensive reported library in the rickettsiae.

In our study, we selected for mutants that showed an altered plaque size phenotype in infected host cell monolayers. Transposon mutations may cause a small plaque phenotype due to any number of defects, including: poor bacterial replication, reduced access to or survival within the cytosol, impaired cytosolic actin-based motility, and defective cell-to-cell spread. It was thus not surprising that we identified genes with a diverse set of predicted functions. Many genes with products predicted to perform bacterial-intrinsic functions (e.g. DNA replication) were identified and are expected to indirectly influence host-pathogen interactions through their role in bacterial growth and division. Other genes had more direct connections to the infectious life cycle and were further characterized in our recent studies to reveal their specific functions in intracellular infection \[[@pone.0197012.ref014],[@pone.0197012.ref020]\]. For example, we previously described transposon mutations that disrupt the *rickA* (Sp34) and *sca2* (Sp2) genes and showed that these gene products are required for two independent phases of *R*. *parkeri* actin-based motility \[[@pone.0197012.ref020]\]. We also identified a transposon insertion (Sp19) in *sca4* gene and showed this encodes a secreted effector that promotes cell-to-cell spread \[[@pone.0197012.ref014]\].

Other genes mutated in this screen have been suggested to play critical roles during the infectious life cycle of other *Rickettsia* species but have yet to be characterized in *R*. *parkeri*. For example, we isolated transposon insertion mutants in the *ompA* (Sp80) and *ompB* (Sp106) genes, encoding the outer membrane proteins OmpA and OmpB. Work with SFG species *R*. *conorii* and *R*. *rickettsii* showed that OmpA and OmpB may regulate adhesion to and/or invasion of host cells \[[@pone.0197012.ref022]--[@pone.0197012.ref025]\]. However, some of this work relied on expression of these proteins in other bacterial species because mutants were not available. Interestingly, targeted knockout of *ompA* in *R*. *rickettsii* via an LtrA group II intron retrohoming system revealed no clear requirement for OmpA in invasion \[[@pone.0197012.ref026]\], suggesting it alone is not necessary. This highlights the importance of studying loss-of-function mutants to reveal gene function. The fact that *ompA* and *ompB* mutants exhibit a small plaque phenotype suggest additional functions of these proteins, putative indirect effects of the truncated products, or simply a need for efficient invasion of neighboring cells after host cells lyse during plaque development. Future work on these mutants should help reveal the relative importance of these proteins during invasion and/or other stages of the *R*. *parkeri* life cycle.

Our screen also revealed genes for which no specific role has been ascribed during the infectious life cycle, although the sequence of their protein products suggests a role in interaction with host cells. These proteins include some with eukaryotic-like motifs such as ankyrin repeats, which often mediate protein-protein interactions \[[@pone.0197012.ref027]\], and are a common motif in secreted bacterial effector proteins or virulence factors that target host pathways \[[@pone.0197012.ref027],[@pone.0197012.ref028]\]. In particular, mutations in genes encoding *R*. *parkeri* orthologs of RARP-1 and RARP-2 from *R*. *typhi* (accession numbers MC1_01745 and MC1_05235, respectively) were identified in our screen (Sp64, Sp116, and Sp39). Work in *R*. *typhi* has revealed that RARP-1 and RARP-2 are secreted into the host cell, but their precise functions remain unknown \[[@pone.0197012.ref029],[@pone.0197012.ref030]\].

Another mystery in rickettsial biology relates to the functional importance of the putative type IV secretion system (T4SS) encoded in their genomes \[[@pone.0197012.ref031]\], which in other species is involved in translocating DNA, nucleoproteins, and effector proteins into host cells \[[@pone.0197012.ref032]\]. Strikingly, the *Rickettsia* T4SS has an unusual expansion of the VirB6-like genes (i.e. Rickettsiales vir homolog, *rvhB6*), which are predicted to encode inner membrane protein components at the base of the T4SS \[[@pone.0197012.ref030],[@pone.0197012.ref031],[@pone.0197012.ref033]\]. Interestingly, we isolated a strain with a transposon insertion mutation in the fifth VirB6-like gene, *rvhB6e* (Sp9). This mutant will prove useful to explore the function of the T4SS in rickettsial infection.

Finally, we identified 20 strains, each carrying a transposon insertion disrupting a gene encoding a hypothetical protein. One of these caused a big plaque phenotype, suggesting enhanced growth or cell-to-cell spread. Further study of these mutants has the potential to reveal the function of these uncharacterized gene products during rickettsial infection. We also identified 25 small plaque mutants with insertions in intergenic regions. In these cases, the mutant phenotype could be caused by transposon insertion into a promoter region that alters gene expression. These mutants may represent tools for exploring gene regulation during the *R*. *parkeri* life cycle.

Overall, our mutant collection provides an important resource that can be used to uncover key bacterial players that regulate rickettsial interactions with their host cells. This will also allow for more direct analysis of gene function in the rickettsiae without the reliance on introducing genes into heterologous organisms. This forward genetics approach has the potential to reveal new insights into rickettsial biology and pathogenesis; however, limitations remain. For example, because the rickettsiae are obligate intracellular pathogens, screens such as these are unlikely to reveal genes that are essential for invasion or intracellular growth. Therefore, we cannot necessarily assess the relative importance of genes not identified in forward genetic screens. Additionally, the reported protocol still has limits with regard to electroporation efficiency and recovery on host cells, which makes it harder to adapt for large-scale mutagenesis work. Continued optimization of the protocols we report---by further characterizing and enhancing transformation efficiency and bacterial viability---will help investigators expand the available toolkit to generate more *Rickettsia* mutants. Additional advancements in rickettsial genetic methods will also be necessary to complement our work and more effectively probe the molecular mechanisms of all genes whose products may control critical host-pathogen interactions.
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